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Abstract
Background: We aimed to assess whether elderly patients with acute venous thromboembolism (VTE) receive
recommended initial processes of care and to identify predictors of process adherence.
Methods:We prospectively studied in- and outpatients aged$65 years with acute symptomatic VTE in a multicenter cohort
study from nine Swiss university- and non-university hospitals between September 2009 and March 2011. We
systematically assessed whether initial processes of care, which are recommended by the 2008 American College of Chest
Physicians guidelines, were performed in each patient. We used multivariable logistic models to identify patient factors
independently associated with process adherence.
Results: Our cohort comprised 950 patients (mean age 76 years). Of these, 86% (645/750) received parenteral
anticoagulation for $5 days, 54% (405/750) had oral anticoagulation started on the first treatment day, and 37% (274/750)
had an international normalized ratio (INR) $2 for $24 hours before parenteral anticoagulation was discontinued. Overall,
35% (53/153) of patients with cancer received low-molecular-weight heparin monotherapy and 72% (304/423) of patients
with symptomatic deep vein thrombosis were prescribed compression stockings. In multivariate analyses, symptomatic
pulmonary embolism, hospital-acquired VTE, and concomitant antiplatelet therapy were associated with a significantly
lower anticoagulation-related process adherence.
Conclusions: Adherence to several recommended processes of care was suboptimal in elderly patients with VTE. Quality of
care interventions should particularly focus on processes with low adherence, such as the prescription of continued low-
molecular-weight heparin therapy in patients with cancer and the achievement of an INR $2 for $24 hours before
parenteral anticoagulants are stopped.
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Introduction
The incidence of acute venous thromboembolism (VTE),
defined as acute deep vein thrombosis (DVT) or pulmonary
embolism (PE), rises exponentially with age [1,2]. In the geriatric
population, VTE not only carries a higher mortality but also a
higher rate of VTE recurrence and major bleeding than in
younger patients [3].
The American College of Chest Physicians (ACCP) Evidence-
based Clinical Practice Guidelines recommend specific processes
of care for the management of patients with acute VTE [4,5].
Several of these processes have the potential to improve patient
outcomes and to reduce the length of hospital stay and health care
costs [6–12]. These recommended processes include the admin-
istration of parenteral anticoagulation for at least five days,
initiation of oral anticoagulation on the first treatment day,
maintenance of an International Normalized Ratio (INR) $2 for
at least 24 hours before parenteral anticoagulation is discontinued,
continued therapy with low-molecular-weight heparin (LMWH) in
patients with cancer, and the use of compression stockings in
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patients with symptomatic DVT [4,5]. Prior studies demonstrated
wide practice variation and suboptimal adherence to these
processes of care [13–15].
Despite the higher VTE incidence and complication rates in
elderly patients, to our knowledge, only two retrospective studies
have examined the adherence to VTE-related processes of care in
patients aged $65 years [16,17]. In a large multicenter
prospective cohort study, we therefore assessed whether elderly
patients aged 65 years or over with VTE received recommended
processes of care in the early phase of VTE and to identify
predictors of process adherence.
Methods
Ethics statement
We asked eligible patients to provide written informed consent.
The study was approved by the Institutional Review Board of each
participating site (Commission cantonale (VD) d’e´thique de la
recherche sur l’eˆtre humain, Commission cantonale d’e´thique de
la recherche, Kantonale Ethikkommission Bern, Kantonale
Ethikkommission Zu¨rich, Kantonale Ethikkommission Kanton
Aargau, Ethikkommission des Kanton St. Gallen, Ethikkommis-
sion des Kantons Thurgau, Ethikkommission Luzern, Ethikkom-
mission Basel). The committees approved the consent procedure of
participants.
Cohort sample
The study was conducted between September 1, 2009 and
March 31, 2011 as part of a prospective, multicenter cohort study
to assess medical outcomes of patients aged $65 years with acute,
symptomatic VTE from all five Swiss university and four high-
volume non-university hospitals [18]. Potential participants were
consecutively identified in the inpatient and outpatient services of
all participating study sites. We defined DVT as the acute onset of
leg pain or swelling plus incomplete compressibility of a venous
segment on ultrasonography or an intraluminal filling defect on
contrast venography) [19]. Because the iliac vein and the inferior
vena cava may be technically difficult to compress, iliac/caval
DVT was defined as abnormal duplex flown patterns compatible
with thrombosis or an intraluminal filling defect on contrast
computed tomography or magnetic resonance imaging venogra-
phy [20]. Given that ultrasonography has a reduced sensitivity and
specificity for distal DVT [21] patients with distal DVT were
included only if the incompressible distal vein transverse diameter
was at least 5 mm. We defined PE as the acute onset of dyspnea,
chest pain, or syncope coupled with a new high-probability
ventilation/perfusion lung scan; a new contrast filling defect on
spiral computed tomography or pulmonary angiography; or the
new documentation of a proximal DVT either by venous
ultrasound or contrast venography [22,23]. Radiographic studies
used to diagnose VTE were interpreted by on-site vascular
specialists or radiologists.
Table 1. Patient Baseline Characteristics
Characteristic n (%)a)
Age.80 years 261 (28)
Female sex 443 (47)
BMI.30 kg/m2 226 (24)
Nursing home care 24 (3)
Higher level of educationalb) 427 (45)
Symptomatic PEc) 654 (69)
Hospital-acquired VTEd) 175 (18)
History of major bleeding 92 (10)
Active cancere) 153 (16)
Cardiovascular comorbidityf) 231 (24)
Diabetes mellitus 147 (15)
Renal impairmentg) 197 (21)
Anemiah) 374 (39)
Low platelet count (,1506109/L) 131 (14)
Concomitant antiplatelet medicationi) 315 (33)
Polypharmacyk) 489 (51)
Abbreviations: BMI = body mass index; PE = pulmonary embolism; VTE = venous thromboembolism.
a)Overall, missing values were 0.5% for BMI, 0.1% for nursing home care, 0.2% for higher level of education, 0.1% for history of major bleeding, 6.6% for hemoglobin
level, and 6.6% for platelet count.
b)High school or post high school attendance.
c)Symptomatic PE with or without a deep vein thrombosis.
d)VTE event occurring during a hospital stay.
e)Requiring chemotherapy, radiotherapy, surgery, or palliative care during the last three months.
f)Acute heart failure or history of heart failure or coronary heart disease.
g)Glomerular filtration rate ,30 ml/min or a history of chronic renal failure.
h)Hemoglobin level ,13 g/dL for men or ,12 g/dL for women.
i)Use of aspirin, clopidogrel, prasugrel, and/or dipyridamol.
k)Concomitant use of more than four drugs.
(n = 950).
doi:10.1371/journal.pone.0100164.t001
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Exclusion criteria were inability to provide informed consent
(i.e., severe dementia), conditions incompatible with follow-up (i.e.,
terminal illness or place of living too far away from the study
center), insufficient German or French speaking ability, thrombo-
sis at a different site than lower limb, catheter-related thrombosis,
or previous enrollment in the cohort. We also excluded patients
who received thrombolytic therapy, surgical treatment (i.e.,
thrombo-/embolectomy), or a vena cava filter.
Treatment of VTE, e.g., the type of anticoagulant used (i.e.,
parenteral anticoagulant followed by vitamin K antagonists or
parenteral anticoagulation alone) and the prescription of com-
pression stockings, was entirely left to the discretion of the
managing physicians.
Baseline data collection
For all enrolled patients, baseline demographic information
(age, gender, weight, height, level of education and place of living),
type (PE, DVT, or both) and occurrence of VTE (hospital-
acquired vs. home-acquired), comorbid conditions (history of
major bleeding, cardiovascular comorbidity, diabetes mellitus,
renal impairment), laboratory findings (anemia, low platelet
count), concomitant use of platelet inhibitors, and the number of
concomitant drug treatments were prospectively collected by
medical record review by trained research nurses and recorded on
standard data collection forms. Information was also gathered on
pharmacological (type, timing, and duration of anticoagulant
treatment) and non-pharmacological treatments (prescription of
compression stockings).
Processes of care
We assessed whether the following five processes of care, which
were recommended in the 2008 ACCP guidelines [4], were
performed in each patient: (1) administration of parenteral
anticoagulants for $5 days; (2) start of oral anticoagulation on
the first treatment day (defined as the administration of the first
dose of vitamin K antagonists within 24 hours after VTE
diagnosis); (3) continuation of parenteral anticoagulants until an
international normalized ratio [INR] $2 for at least 24 hours; (4)
continued use of LMWH without switching to vitamin K
antagonists in patients with an active cancer (defined as active
solid or hematologic cancers requiring chemotherapy, radiother-
apy, or surgery within the previous three months); and (5)
prescription of compression stockings in patients with symptomatic
DVT. For our analysis of processes of care 1–3, we considered
only patients who were switched from parental anticoagulants to
vitamin K antagonists within 21 days. We collected data up to 90
days following the index VTE.
Figure 1. Flow chart. Abbreviations: DVT= deep vein thrombosis. A) Multiple reasons for exclusion may apply.
doi:10.1371/journal.pone.0100164.g001
Table 2. Adherence to Recommended Processes of Care.
Processes of care n/N (%)a)
1) Duration of parenteral anticoagulation $5 days 645/750 (86)
2) Start of oral anticoagulation on the first treatment day 405/750 (54)
3) Parenteral anticoagulation until an INR $2 for at least 24 hours 274/750 (37)
4) Continued treatment with LMWH for active cancer 53/153 (35)
5) Prescription of compression stockings for symptomatic DVT 304/423 (72)
Abbreviations: INR = international normalized ratio; LMWH= low-molecular-weight heparin; DVT = deep vein thrombosis.
a)Denominators change because of different subgroup analyses.
For instance, for processes of care 1–3, we analyzed the 750 patients who were switched from LMWH to oral anticoagulants. For processes of care 4 and 5, we analyzed
the 153 with cancer and the 423 patients with symptomatic DVT, respectively.
doi:10.1371/journal.pone.0100164.t002
Adherence to Processes of Care
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Statistical analyses
Baseline characteristics are shown as numbers and percentages.
Analyzed and non-analyzed patients were compared using the chi-
squared test or the Wilcoxon rank-sum test as appropriate. For
each of the five processes of care, as well as for the combination of
the three anticoagulation-related processes of care, the number
and proportion of guideline adherence was calculated.
We used logistic regression to explore associations between
baseline patient characteristics shown in Table 1 and the
adherence to three processes of care: (1) duration of parenteral
anticoagulation $5 days, (2) start of oral anticoagulation on the
first treatment day, and (3) continuation of parenteral anticoag-
ulation until the INR is $2 for 24 hours. The sample sizes of the
subpopulations with cancer and symptomatic DVT were not large
enough to conduct robust multivariable analyses. For missing
values, we performed multiple imputation by chained equations
[24], assuming missing data to be missing at random. A total of
twenty imputed datasets were generated based on all baseline
variables, the three outcome variables and study site. Adjusted
odds ratios (OR) and corresponding 95% confidence intervals (CI)
and P-values were calculated applying Rubin’s rules [25].
Adjustment was done for all baseline variables as fixed effects
and study site as a random effect in a mixed-effects logistic model.
In a sensitivity analysis, a complete case analysis was performed,
excluding any cases with missing values. All analyses were
performed using STATA statistical software, Version 12.0.
Results
Patient identification and baseline characteristics
Of 1863 patients screened during the study period, 1003 were
originally enrolled in the cohort study (Figure 1). Of these, 53 were
excluded, leaving a study sample of 950 analyzed patients. Non-
analyzed patients were statistically significantly older (mean age 77
vs. 76 years; P,0.001) and more likely to be women (59% vs.
47%; P,0.001) than analyzed patients.
Overall, 28% of patients were aged .80 years, 47% (443/950)
were women, and 3% (24/950) were nursing home residents
(Table 1). Eighteen percent (175/950) had hospital-acquired VTE.
Of the 775 patients who developed VTE in an outpatient setting
(community-acquired VTE), 589 (76%) were admitted to the
hospital.
Adherence to recommended processes of care
Overall, 750 patients were switched from parental anticoagu-
lants to vitamin K antagonists. Of these, 86% (645/750) received
parenteral anticoagulation for $5 days, 54% (405/750) had oral
anticoagulation started on the first treatment day, and 37% (274/
750) had an INR $2 for $24 hours before parenteral anticoag-
ulation was discontinued (Table 2). Only 18% (138/750) of
patients received all three anticoagulation-related processes of
care.
Among the 153 patients with active cancer, only 35% (53/153)
received continued LMWH, 25% (39/153) received unfractionat-
ed heparin or fondaparinux followed by oral anticoagulation, 23%
(35/153) unfractionated heparin or fondaparinux alone, 14% (21/
153) LMWH followed by oral anticoagulation, 2% (3/153) oral
anticoagulation alone, and 1% (2/153) no anticoagulation at all.
Of 423 patients who had symptomatic DVT, 72% (304/423) were
prescribed compression stockings.
There was some variation by type of VTE. As shown in Table 3,
patients with PE were more likely to have an INR $2 for $
24 hours before parenteral anticoagulation was stopped than
patients with DVT only (40% vs. 27%; P,0.001). On the other
hand, patients with cancer who had DVT only were more likely to
receive continued treatment with LMWH than patients with PE
(52% vs. 26%; P=0.001).
There was a substantial variation across study sites: adherence
varied from 79% to 94% for parenteral anticoagulation for $5
days, from 47% to 62% for the start of oral anticoagulation on the
first treatment day, from 13% to 50% for an INR $2 for $
24 hours before parenteral anticoagulation was discontinued, from
0% to 64% for continued LMWH in patients with cancer, and
from 61% to 90% for the prescription of compression stockings in
patients with symptomatic DVT.
Predictors of process adherence
In multivariable analyses, patients with hospital-acquired VTE
(OR, 2.60; 95% CI, 1.10–6.14) were statistically significantly more
likely to receive parenteral anticoagulation for$5 days (Figure 2A).
Patients with hospital-acquired VTE (OR, 0.37; 95% CI, 0.23–
0.60) and overt PE (OR, 0.70; 95% CI, 0.50–0.99) were less likely
to receive oral anticoagulation on the first treatment day
(Figure 2B). Finally, patients with overt PE (OR, 1.50; 95% CI,
1.02–2.20) and cardiovascular comorbidity (OR, 1.52; 95% CI,
1.01–2.28) were more likely to continue parenteral anticoagulation
until the INR was $2 for 24 hours, whereas patients with
concomitant antiplatelet medication were less likely to have two
INR values $2 for 24 hours before parenteral anticoagulation was
stopped (OR, 0.61; 95% CI, 0.41–0.92) (Figure 2C). Age .80
years was not a significant predictor of process adherence. When
patients with missing values were excluded from analyses, results
remained similar.
Table 3. Stratified Analyses by Type of Venous Thromboembolism.
Overt PEa) n/N (%) DVT only n/N (%) P-value
Parenteneral anticoagulation for $5 days 465/546 (85) 180/204 (88) 0.281
Initiation of oral anticoagulation on the first treatment day 283/546(52) 122/204 (60) 0.051
INR $2 during at least 24 hours before discontinuation of
parenteral anticoagulation
219/546 (40) 55/204 (27) ,0.001
Continued treatment with LMWH for cancer 26/101 (26) 27/52 (52) 0.001
Prescription of compression stockings for symptomatic DVT 88/127 (69) 216/296 (73) 0.440
Abbreviations: PE = pulmonary embolism; DVT= deep vein thrombosis; INR = international normalized ratio; LMWH= low-molecular-weight heparin.
a)With or without concomitant DVT.
doi:10.1371/journal.pone.0100164.t003
Adherence to Processes of Care
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Discussion
In this prospective multicenter cohort study of 950 elderly
patients with acute symptomatic VTE, we found that adherence to
five recommended processes of care was variable and partially
suboptimal. The adherence rate varied from 86% for treatment
with parenteral anticoagulants for at least five days to a mere 35%
for continued treatment with LMWH in patients with active
cancer. Overall, our findings are consistent with prior studies
demonstrating that the use of recommended processes of care and
the achievement of treatment goals for patients with VTE leaves
room for improvement [6,13–17,26].
If anything, adherence rates were even lower in our elderly
population (mean age 76 years) for several processes of care than
in previous studies enrolling younger patients with VTE (mean age
56–66 years) [6,13–15]. Compared to a retrospective study of U.S.
veterans in which oral anticoagulation was initiated on the first
treatment day in 64% of cases [6], we found a substantially lower
rate in our study sample (54%). In a prospective study of Canadian
outpatients with VTE [15], 60% of patients with cancer-related
VTE received LMWH monotherapy compared to 35% in our
study. While the proportion of patients who had parenteral
anticoagulation continued until an INR value $2.0 for 24 hours
was 37% only in our sample, this target was achieved in about
50% of patients in younger patients [13,14].
Our results demonstrating a low adherence rate to anticoagu-
lation-related processes of care in elderly patients are consistent
with prior evidence showing that the rate of anticoagulation is low
in hospitalized elderly patients with atrial fibrillation [27]. Elderly,
multimorbid medical inpatients have also a low rate of venous
thromboprophylaxis [28]. It remains unclear whether the low
adherence rate is due to lack of physicians’ knowledge, physicians’
fear to induce bleeding, the presence of comorbid conditions that
are not compatible with guideline adherence, or patient prefer-
ences [29]. For instance, elderly patients with cancer who develop
VTE are more likely to have severe renal failure and therefore,
may not be candidates for extended LMWH treatment. Similarly,
although LMWHs seem to be acceptable to patients with cancer
[30], many elderly patients may prefer to receive oral anticoag-
ulants rather than daily injections with LMWH. One study found
that 30% of physicians did not believe it is necessary to have a
therapeutic INR for $2 days before discontinuing heparin [14].
Prior evidence about the effect of age on VTE-related
anticoagulation practices is limited. While age did not influence
the duration of anticoagulant therapy in one study [16], older
patients were more likely to have continuation of parenteral
anticoagulation until INR was $2 for 24 hours in another study
[6]. In an Italian registry, compression stockings were 1.6 times
more likely to be prescribed in patients aged 40–60 years than in
patients aged .80 years [31].
To our knowledge, there are no studies examining the
effectiveness of interventions to improve anticoagulation-related
processes of care for established VTE. Although evidence from
studies on VTE prophylaxis suggests that active, multifaceted
strategies, including provider education, electronic alerts, and
regular audit and feedback to medical staff, appear to be the most
promising interventions [29,32–34], whether such interventions
have the potential to improve therapeutic anticoagulation-related
care and outcomes of VTE must be further examined.
We could not identify a clear pattern of consistent predictors of
suboptimal process adherence that may become potential targets
for quality improvement interventions. While hospital-acquired
VTE was associated with delayed initiation of oral anticoagula-
tion, patients with the same condition were more likely to get
Figure 2. A. Predictors for using parenteral anticoagulation for
$5 days (n=750). Abbreviations: OR= odds ratio; CI = confidence
interval; BMI = body mass index; VTE = venous thromboembolism;
PE =pulmonary embolism. A. a) Adjusted for all baseline characteristics
shown in Table 1 as a fixed effect and for study site as a random effect.
A selection of variables is displayed in the figures to improve legibility
i.e. age, sex and all variables with statistical significant numbers. B.
Predictors for starting oral anticoagulation on the first
treatment day (n=750). C. Predictors for continuing parenteral
anticoagulation until an international normalized ratio of $2
for 24 hours (n=750).
doi:10.1371/journal.pone.0100164.g002
Adherence to Processes of Care
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e100164
parenteral anticoagulation for $5 days. Given that hospitalized
patients often undergo diagnostic or therapeutic procedures,
parenteral anticoagulation is easier to control and thus possibly
preferred. Similarly, patients with PE, who are hospitalized in
most instances, were less likely to get oral anticoagulants on the
first treatment day but were more likely to have two INR values $
2.0 before parental anticoagulation was stopped. Our finding that
patients with concomitant antiplatelet therapy were less likely to
have two INR values before stopping parenteral anticoagulation
may reflect physicians’ underlying fear of bleeding in such patients
[29].
Our study has potential limitations. First, our sample may not
reflect the full spectrum of elderly patients with VTE because
analyzed patients were younger and more likely to be men than
non-analyzed patients. Moreover, given that patients were
enrolled from hospital inpatient and outpatient services, patients
with DVT who were diagnosed and entirely managed in the
primary care or nursing home setting may be underrepresented in
our sample. This could explain the relatively high proportion of
patients who had symptomatic PE (69%) in our cohort. Because
we excluded patients with severe dementia who may have a lower
process adherence, our study may overestimate the true process
adherence rates [35]. However, given that our multicenter cohort
study enrolled a broad population of in- and outpatients aged $65
years from university- and non-university hospitals, our study
sample should be fairly representative for elderly patients with
VTE. Second, as treating physicians were aware that patients were
included in a cohort study, they may have altered their behavior
and better followed recommended processes of care. Thus, we
cannot exclude that the adherence rates in our study may
overestimate the true process adherence rates. Third, because data
on physician characteristics (e.g., type and duration of training)
were not available in our database, we could not examine whether
these factors were associated with adherence to VTE-related
processes of care. Similarly, we could not explore potential
physician barriers to antithrombotic guideline adherence in elderly
patients with VTE, which must be done in a further study. Fourth,
because patient enrollment in our study started in 2009, we used
the 2008 version of the ACCP guidelines as a benchmark for
VTE-related quality of care and not the latest 2012 version [4,5].
However, the recommendations with respect to the processes of
care examined in our study are basically the same in both versions.
Finally, our goal was to examine adherence rates to initial
processes of care in elderly patients with VTE and to identify
predictors of process adherence. Thus, we did not examine the
impact of process adherence on patient outcomes, which must be
done in another study.
In conclusion, adherence to recommended processes of care was
variable and partially suboptimal in elderly patients with VTE.
Additional efforts are needed to increase process adherence and
quality of care in such patients. Quality of care interventions
should particularly focus on recommended processes with low
adherence rates, such as the prescription of continued LMWH in
patients in cancer and the achievement of an INR $2 for $
24 hours before parenteral anticoagulants are stopped.
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